H. Lundbeck As - Facts About Epilepsy

LONDON (Reuters) - Danish drugmaker Lundbeck will continue to sell a drug used in U.S. executions since pulling it off the market would be bad for some patients with severe epilepsy, its CEO said on Wednesday.The company has found itself at the ...

Vigabatrin is an antiepileptic drug that inhibits the catabolism of gamma-Aminobutyric acid (GABA) by irreversibly inhibiting GABA transaminase. It is manufactured and distributed by Lundbeck Inc. (formerly Ovation Pharma ). Lundbeck Inc. is a wholly owned subsidiary of H. Lundbeck A/S (Denmark). ...

In March 2009, H. Lundbeck A/S (Lundbeck) acquired Ovation Pharmaceuticals, Inc. (now Lundbeck Inc.). As part of the acquisition Lundbeck obtained the rights for clobazam in the US, a product in development for patients with Lennox-Gastaut syndrome (LGS). Following analysis of the ...

), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: Lundbeck plans to launch Sabril in the United States in the third quarter.. Sabril is indicated as monotherapy for pediatric patients one month to two years of age with infantile ...

Lundbeck's Sabril first drug approved by FDA for treatment of rare seizure disorder in infantsThe Food and Drug Administration on Friday approved the first drug to treat infantile spasms, a rare disorder that can cause hundreds of seizures per day in children ...

PK) yesterday announced yet another setback to its late-stage pipeline, with the news that it and partner Solvay (SVYSY. Yesterday, the share price reaction was much more muted, down 3% at ?101.75, indicating the lack of value that analysts had prescribed to ...

a specialty pharmaceutical company focusing on central nervous system disorders (CNS). - The acquisition of Ovation realises Lundbeck's strategic goal of building a US commercial platform and will contribute to Lundbeck's mid and long-term growth prospects - Ovation has an attractive portfolio ...

Topic: H. Lundbeck As

Lundbeck won't pull drug used in U.S. executions

Vigabatrin

clobazam

Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies

FDA approves first drug for infantile spasms

Lundbeck's Late Stage Pipeline Keeps Looking Thinner

H. Lundbeck A/S (DK) - Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc.

From Around the Web

Video Gallery

Follow this Topic with...